Advanced search
1 file | 780.61 KB Add to list

Focus on 16p13.3 locus in colon cancer

Evi Mampaey (UGent) , Annelies Fieuw (UGent) , Thalia Van Laethem (UGent) , Liesbeth Ferdinande (UGent) , Kathleen Claes (UGent) , Wim Ceelen (UGent) , Yves Van Nieuwenhove (UGent) , Piet Pattyn (UGent) , Marc De Man (UGent) , Kim De Ruyck (UGent) , et al.
(2015) PLOS ONE. 10(7).
Author
Organization
Abstract
Background : With one million new cases of colorectal cancer (CRC) diagnosed annually in the world, CRC is the third most commonly diagnosed cancer in the Western world. Patients with stage I-III CRC can be cured with surgery but are at risk for recurrence. Colorectal cancer is characterized by the presence of chromosomal deletions and gains. Large genomic profiling studies have however not been conducted in this disease. The number of a specific genetic aberration in a tumour sample could correlate with recurrence-free survival or overall survival, possibly leading to its use as biomarker for therapeutic decisions. At this point there are not sufficient markers for prediction of disease recurrence in colorectal cancer, which can be used in the clinic to discriminate between stage II patients who will benefit from adjuvant chemotherapy. For instance, the benefit of adjuvant chemotherapy has been most clearly demonstrated in stage III disease with an approximately 30 percent relative reduction in the risk of disease recurrence. The benefits of adjuvant chemotherapy in stage II disease are less certain, the risk for relapse is much smaller in the overall group and the specific patients at risk are hard to identify. Materials and Methods : In this study, array-comparative genomic hybridization analysis (array-CGH) was applied to study high-resolution DNA copy number alterations in 93 colon carcinoma samples. These genomic data were combined with parameters like KRAS mutation status, microsatellite status and clinicopathological characteristics. Results : Both large and small chromosomal losses and gains were identified in our sample cohort. Recurrent gains were found for chromosome 1q, 7, 8q, 13 and 20 and losses were mostly found for 1p, 4, 8p, 14, 15, 17p, 18, 21 and 22. Data analysis demonstrated that loss of chromosome 4 is linked to a worse prognosis in our patients series. Besides these alterations, two interesting small regions of overlap were identified, which could be associated with disease recurrence. Gain of the 16p13.3 locus (including the RNA binding protein, fox-1 homolog gene, RBFOX1) was linked with a worse recurrence-free survival in our patient cohort. On the other hand, loss of RBFOX1 was only found in patients without disease recurrence. Most interestingly, above mentioned characteristics were also found in stage II patients, for whom there is a high medical need for the identification of new prognostic biomarkers. Conclusions : In conclusion, copy number variation of the 16p13.3 locus seems to be an important parameter for prediction of disease recurrence in colon cancer.
Keywords
TUMOR MICROSATELLITE-INSTABILITY, COLORECTAL-CANCER, COPY NUMBER ALTERATIONS, COMPARATIVE GENOMIC HYBRIDIZATION, STAGE-II, INTEGRATED ANALYSIS, ADJUVANT TREATMENT, METAANALYSIS, IDENTIFICATION, PROGRESSION

Downloads

  • Focus on 16p13.3 Locus in Colon Cancer.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 780.61 KB

Citation

Please use this url to cite or link to this publication:

MLA
Mampaey, Evi et al. “Focus on 16p13.3 Locus in Colon Cancer.” PLOS ONE 10.7 (2015): n. pag. Print.
APA
Mampaey, E., Fieuw, A., Van Laethem, T., Ferdinande, L., Claes, K., Ceelen, W., Van Nieuwenhove, Y., et al. (2015). Focus on 16p13.3 locus in colon cancer. PLOS ONE, 10(7).
Chicago author-date
Mampaey, Evi, Annelies Fieuw, Thalia Van Laethem, Liesbeth Ferdinande, Kathleen Claes, Wim Ceelen, Yves Van Nieuwenhove, et al. 2015. “Focus on 16p13.3 Locus in Colon Cancer.” Plos One 10 (7).
Chicago author-date (all authors)
Mampaey, Evi, Annelies Fieuw, Thalia Van Laethem, Liesbeth Ferdinande, Kathleen Claes, Wim Ceelen, Yves Van Nieuwenhove, Piet Pattyn, Marc De Man, Kim De Ruyck, Nadine Van Roy, Karen Geboes, and Stéphanie Laurent. 2015. “Focus on 16p13.3 Locus in Colon Cancer.” Plos One 10 (7).
Vancouver
1.
Mampaey E, Fieuw A, Van Laethem T, Ferdinande L, Claes K, Ceelen W, et al. Focus on 16p13.3 locus in colon cancer. PLOS ONE. 2015;10(7).
IEEE
[1]
E. Mampaey et al., “Focus on 16p13.3 locus in colon cancer,” PLOS ONE, vol. 10, no. 7, 2015.
@article{6916441,
  abstract     = {Background : With one million new cases of colorectal cancer (CRC) diagnosed annually in the world, CRC is the third most commonly diagnosed cancer in the Western world. Patients with stage I-III CRC can be cured with surgery but are at risk for recurrence. Colorectal cancer is characterized by the presence of chromosomal deletions and gains. Large genomic profiling studies have however not been conducted in this disease. The number of a specific genetic aberration in a tumour sample could correlate with recurrence-free survival or overall survival, possibly leading to its use as biomarker for therapeutic decisions. At this point there are not sufficient markers for prediction of disease recurrence in colorectal cancer, which can be used in the clinic to discriminate between stage II patients who will benefit from adjuvant chemotherapy. For instance, the benefit of adjuvant chemotherapy has been most clearly demonstrated in stage III disease with an approximately 30 percent relative reduction in the risk of disease recurrence. The benefits of adjuvant chemotherapy in stage II disease are less certain, the risk for relapse is much smaller in the overall group and the specific patients at risk are hard to identify. 
Materials and Methods : In this study, array-comparative genomic hybridization analysis (array-CGH) was applied to study high-resolution DNA copy number alterations in 93 colon carcinoma samples. These genomic data were combined with parameters like KRAS mutation status, microsatellite status and clinicopathological characteristics. 
Results : Both large and small chromosomal losses and gains were identified in our sample cohort. Recurrent gains were found for chromosome 1q, 7, 8q, 13 and 20 and losses were mostly found for 1p, 4, 8p, 14, 15, 17p, 18, 21 and 22. Data analysis demonstrated that loss of chromosome 4 is linked to a worse prognosis in our patients series. Besides these alterations, two interesting small regions of overlap were identified, which could be associated with disease recurrence. Gain of the 16p13.3 locus (including the RNA binding protein, fox-1 homolog gene, RBFOX1) was linked with a worse recurrence-free survival in our patient cohort. On the other hand, loss of RBFOX1 was only found in patients without disease recurrence. Most interestingly, above mentioned characteristics were also found in stage II patients, for whom there is a high medical need for the identification of new prognostic biomarkers. 
Conclusions : In conclusion, copy number variation of the 16p13.3 locus seems to be an important parameter for prediction of disease recurrence in colon cancer.},
  articleno    = {e0131421},
  author       = {Mampaey, Evi and Fieuw, Annelies and Van Laethem, Thalia and Ferdinande, Liesbeth and Claes, Kathleen and Ceelen, Wim and Van Nieuwenhove, Yves and Pattyn, Piet and De Man, Marc and De Ruyck, Kim and Van Roy, Nadine and Geboes, Karen and Laurent, Stéphanie},
  issn         = {1932-6203},
  journal      = {PLOS ONE},
  keywords     = {TUMOR MICROSATELLITE-INSTABILITY,COLORECTAL-CANCER,COPY NUMBER ALTERATIONS,COMPARATIVE GENOMIC HYBRIDIZATION,STAGE-II,INTEGRATED ANALYSIS,ADJUVANT TREATMENT,METAANALYSIS,IDENTIFICATION,PROGRESSION},
  language     = {eng},
  number       = {7},
  pages        = {15},
  title        = {Focus on 16p13.3 locus in colon cancer},
  url          = {http://dx.doi.org/10.1371/journal.pone.0131421},
  volume       = {10},
  year         = {2015},
}

Altmetric
View in Altmetric
Web of Science
Times cited: